

# A general, efficient and stereospecific route to sphingosine, sphinganine, phytosphingosines and their analogs

Ye Cai, Chang-Chun Ling and David R. Bundle\*

Received 17th November 2005, Accepted 4th January 2006

First published as an Advance Article on the web 26th January 2006

DOI: 10.1039/b516333a

Sphingosine, sphinganine and phytosphingosines and their analogs were synthesized by an aldol condensation between an iminoglycinate bearing a (+)-(1*R*,2*R*,5*R*)-2-hydroxy-3-pinane group as chiral auxiliary and an appropriate aldehyde. All condensations proceeded with excellent enantioselectivity to generate the (2*S*,3*R*)-*D*-*erythro* structures in good yields.

## Introduction

Sphingosines, sphinganines (dihydrosphingosines) and phytosphingosines are common long-chain structural constituents of sphingolipids. This class of lipid is unusual because they bear a small positive charge at neutral pH as a consequence of intramolecular hydrogen bonding.<sup>1</sup> This property enables them to cross membranes or move between membranes with ease. The sphingolipids are essential components of the plasma membrane of eukaryotic cells, where they are typically found in the outer leaflet. Although particularly abundant in mammalian cells, they are also present in bacteria and fungi,<sup>2</sup> plants<sup>3</sup> and marine organisms.<sup>4</sup> In addition to their structural functions, they are also involved in various biological activities and play critical roles in many physiological processes, including modulation of immune response, signalling and cellular recognition.<sup>5</sup> Sphingosine and sphinganine can both strongly inhibit protein kinase C<sup>6</sup> and their ceramide derivatives are potent stimulators of the mammalian immune system.<sup>7</sup> Phytosphingosine is a potential heat stress signal in yeast cells,<sup>8</sup> and some of its derivatives exhibit important physiological activities. For example, KRN7000, an  $\alpha$ -galactosylphytosphingosine derivative isolated from a marine sponge, binds to CD1d protein on antigen presenting cells and is a powerful immunostimulant of natural killer T (NKT) cells.<sup>9</sup> Recognition of the glycolipid-CD1d complex by NKT cells results in the production of several cytokines such as interferon- $\gamma$  (IFN- $\gamma$ ) and interleukins (IL)-12 and -4.

Due to their biological significance, as well as the complication of isolation from natural sources in homogeneous form, a great deal of effort has been devoted to the synthesis of this class of compounds.<sup>10</sup> Despite their structural diversity, sphingoid bases share a common (2*S*,3*R*)-*D*-*erythro* amino alcohol moiety. Of all the methodologies, strategies based on diastereoselective asymmetric synthesis are the most challenging. Solladié-Cavallo and Koessler<sup>11</sup> were the first to achieve the diastereoselective synthesis of natural sphingosine using an aldol condensation strategy. These authors employed a titanium enolate derived from an iminoglycinate bearing a (+)-(1*R*,2*R*,5*R*)-2-hydroxy-3-pinane group as chiral auxiliary. When condensing with (*E*)-2-hexadecenal the desired (2*S*,3*R*)-*D*-*erythro* structure was elegantly constructed in just one step and was found to be the only diastereoisomer isolated.

This methodology was subsequently used by Li *et al.* to synthesize the deuterium and tritium labelled sphingosines,<sup>12</sup> and by Shioiri and Irako to prepare sulfobacin A.<sup>13</sup> Vo-Hoang *et al.* recently reported minor modifications for the synthesis of the natural sphingosine.<sup>14</sup> To the best of our knowledge this methodology has not been used to synthesize other sphingoid derivatives.

We were interested in extending Solladié-Cavallo's methodology as a general route to synthesize other members of the sphingoid family such as the truncated sphingosine (**1**),<sup>15</sup> sphinganines (**2a–c**), phytosphingosine (**3**) and even its 4-epimer (**4**) (Fig. 1). This appeared attractive since the stereo and enantiomeric outcome of the aldol condensation should be dictated by the (+)-(1*R*,2*R*,5*R*)-2-hydroxy-3-pinane auxiliary while the stereochemistry of the aldehydes should have little effect.





Fig. 1

## Results and discussions

In research that targets ganglioside based cancer vaccines, we have designed a truncated sphingosine **1**<sup>15</sup> as a versatile aglycone for the synthesis of glycolipid, tumour-associated antigens.<sup>16</sup> Compound **1** conserves the (2*S*,3*R*)-*D*-*erythro* element found in natural sphingosine, while permitting flexible carbohydrate epitope–protein conjugation strategies *via* either the amino group or the double bond. In addition, the terminal double bond allows the transformation of oligosaccharides bearing **1** into the natural oligosaccharide bearing 18-carbon ceramide through a metathesis reaction with 1-pentadecene.<sup>17,15b,c</sup> We have designed a highly efficient process to prepare **1** on a large scale from 1,2-*O*-isopropylidene- $\alpha$ -D-glucofuranose.<sup>15a</sup> As seen in Scheme 1, compound **1** can be prepared *via* Solladié-Cavallo's route by condensing iminoglycinate **5** with acrolein **6**.

The literature reports the preparation of iminoglycinate **5** by condensation of (+)-(1*R*,2*R*,5*R*)-2-hydroxy-3-pinane with ethyl glycinate.<sup>18</sup> When the aldol condensation with acrolein was first carried out using CITi(OP*i*-*t*)<sub>3</sub> and NEt<sub>3</sub> as reagents, a 1:1 mixture


Alberta Ingenuity Center for Carbohydrate Science, Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada. E-mail: dave.bundle@ualberta.ca



**Scheme 1** Reagents and conditions: (a)  $\text{CITi}(\text{OEt})_3$ ,  $\text{NEt}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 72% or  $\text{CITi}(\text{OPr-}i)_3$ ,  $\text{NEt}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 70%; (b) 1N  $\text{HCl}$ , THF, 82%; (c) 2M  $\text{LiBH}_4$ , THF–MeOH, 74%.

of ethyl and isopropylesters was obtained due to a partial exchange of the ethoxy group in the glycinate ester with the isopropoxy group of the reagent. This exchange was also reported in Solladié-Cavallo's original publication.<sup>11</sup> However, the desired adducts **7** ( $\text{R}^1 = \text{Et}$ , and  $i\text{-Pr}$ ), were obtained in 70% yield and each was found to be the only diastereoisomer by NMR spectroscopy. To simplify the analysis, we also performed the reaction using  $\text{NEt}_3$  and  $\text{CITi}(\text{OEt})_3$  (which still contained  $\sim 10\%$   $\text{CITi}(\text{OPr-}i)_3$ ) and as expected, adduct **7** ( $\text{R}^1 = \text{Et}$ ) was obtained in 72% yield, as the major product, as detected by NMR spectroscopy. No 1,4-Michael addition products were observed in either case ( $\text{R}^1 = \text{Et}$  or  $i\text{-Pr}$ ). The ethyl and isopropyl adducts **7** were both smoothly hydrolyzed in 1 M  $\text{HCl}$  in THF to yield **8** in 82% yield. Furthermore, the chiral auxiliary was recovered and could be recycled to prepare the iminoglycinate **5**. The free amino-ester **8** ( $\text{Et}$  or  $i\text{-Pr}$ ) was reduced with  $\text{LiBH}_4$  in a mixture of methanol and THF at room temperature to afford the desired truncated sphingosine analogue **1** in 74% yield.


This strategy was applied to the asymmetric syntheses of sphinganine (Scheme 2). In the literature, sphinganines are normally prepared from the hydrogenation of expensive sphingosines,<sup>19</sup> carbohydrates,<sup>20</sup> or L-serine<sup>21</sup> in six or more steps. However, using the strategy shown in Scheme 2, various sphinganines with different aliphatic chain lengths were successfully prepared in a concise manner. Treating the iminoglycinate **5** with three



**Scheme 2** Reagents and conditions: (a)  $\text{CITi}(\text{OEt})_3$ ,  $\text{NEt}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (b) 1N  $\text{HCl}$ , THF; (c)  $\text{LiAlH}_4$ , THF, reflux.

aldehydes (**9a–c**) in the presence of  $\text{CITi}(\text{OEt})_3$  and  $\text{NEt}_3$ , the corresponding aldol adducts (**10a–c**) were obtained in yields that ranged from 83 to 87%. NMR spectroscopy revealed that only one diastereoisomer was obtained in each case. Imines (**10a–c**) were hydrolyzed under acidic conditions to afford intermediate amines **11a–c** in high yields (80–85%); and once again, the chiral auxiliary was recovered. Final reductions using  $\text{LiAlH}_4$  in refluxing THF gave the desired sphinganines (**2a–c**) in 78–85%.

Following the success in the syntheses of truncated sphingosine **1** and sphinganines **2a–c**, the D-ribo- and L-lyxo-phytosphingosines were the logical synthetic targets for extension of the methodology. Phytosphingosines differ from sphingosines and sphinganines by an additional stereocenter at C-4. Like sphinganines and sphingosines, the chemical synthesis of phytosphingosines usually employs carbohydrates<sup>22</sup> or amino acids<sup>23</sup> as starting materials, and a few syntheses are based on asymmetric synthesis.<sup>24</sup> In order to prepare phytosphingosine **3** and its 4-epimer **4**, aldehydes **14** and **15** are required. We chose to use the methoxymethyl group (MOM) for protection of the  $\alpha$ -hydroxyl group, because this group is acid-sensitive and can be easily removed during the hydrolysis of the imine linkage. The two aldehydes were prepared from **12** and **13** by Dess–Martin oxidation.<sup>25</sup> Both **12** and **13** were synthesized from the commercially available 1-hexadecene according to known literature procedures (Scheme 3).<sup>24e,26</sup>



**Scheme 3** Reagents and conditions: (a) Dess–Martin periodinane,  $\text{CH}_2\text{Cl}_2$ , Py, RT; (b)  $\text{CITi}(\text{OEt})_3$ ,  $\text{NEt}_3$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (c) 1N  $\text{HCl}$ , THF, RT; (d)  $\text{LiAlH}_4$ , THF, reflux.

Condensation of the aldehydes **14** and **15** with **5** proceeded well to give **16** and **17** in excellent yields (83–91%) and high diastereoselectivity. As predicted, the stereochemistry at the  $\alpha$ -position of the aldehydes did not influence the stereo- and enantioselectivity of the aldol condensation. Treatment of **16** or **17** with 1N  $\text{HCl}$  smoothly cleaved both the imine and the MOM protecting group; intermediates **18** and **19** spontaneously

lactonized to afford **20** and **21**, and were isolated as the hydrochloride salt in 83 and 79% yield. The stereochemistry of the lactones was confirmed by comparing the coupling patterns and the  $^3J_{2,3}$  coupling constants with literature data.<sup>24e</sup> Finally, both lactones were reduced with  $\text{LiAlH}_4$  in refluxing THF to give the desired *D-ribo*-phytosphingosine (**3**) and its 4-epimer, *L-lyxo*-phytosphingosine (**4**) in 82 and 80% yields. The overall yield from 1-hexadecene was greater than 45% in both cases.

The stereochemistry of the synthesized sphingoids was determined by NMR spectroscopy. For example, for compound **1**, in methanol- $d_4$ , H-2 appeared as a ddd pattern at 2.77 ppm, with  $J_{1a,2} \sim 4.5$  Hz,  $J_{1b,2} \sim 6.8$  Hz and  $J_{2,3} \sim 6.4$  Hz. H-3 also appeared as a ddd pattern, with  $J_{3,4} \sim 6.1$  Hz. This is in agreement with the coupling patterns of the corresponding protons of the natural sphingosine, as reported in the literature.<sup>11</sup> It is also consistent with a similar compound prepared by another route.<sup>15a</sup> For sphinganine derivatives **2a–c**, phytosphingosine **3** and its 4-epimer **4**, unfortunately, most of the literature NMR data were recorded in pyridine- $d_5$ , DMSO- $d_6$  or chloroform- $d$ . In these solvents, due to complications resulting from coupling with the attached hydroxyl proton as well as aggregation in some solvents (such as chloroform- $d$ ) most of the key protons appear either as broad resonances or as multiplets. Rarely were coupling constants for these protons reported. We discovered all these compounds gave well resolved NMR spectra in methanol- $d_4$ . With the suppression of coupling to the hydroxyl protons, most of the key coupling constants could be extracted. For example, for sphinganine **2b**, the H-2 resonated at 2.70 ppm as a ddd and H-3 at 3.49 as a ddd, with  $J_{1a,2} \sim 4.2$  Hz,  $J_{1b,2} \sim 7.6$  Hz and  $J_{2,3} \sim 5.4$  Hz; for phytosphingosine **3**, the H-2 appeared as a ddd at 2.94 ppm, H-3 as a dd at 3.33 ppm and H-4 as a ddd at 3.51 ppm, with  $J_{1a,2} \sim 4.2$  Hz,  $J_{1b,2} \sim 6.6$  Hz,  $J_{2,3} \sim 5.7$  Hz and  $J_{3,4} \sim 7.8$  Hz; in addition, for the phytosphingosine 4-epimer **4**, H-2 appeared as a ddd at 2.93 ppm, H-3 as a dd at 3.32 ppm and H-4 as a ddd at 3.67 ppm, with  $J_{1a,2} \sim 4.2$  Hz,  $J_{1b,2} \sim 7.0$  Hz,  $J_{2,3} \sim 7.0$  Hz and  $J_{3,4} \sim 2.7$  Hz. That the compounds have the same (2*S*,3*R*)-*D-erythro* configuration is supported by the observation that similar  $J_{2,3}$  coupling constants (5.4–7.0 Hz) were observed for the newly formed C2–C3 linkages when comparing to **1** ( $J_{2,3} \sim 6.4$  Hz). Optical rotations were also consistent with literature reports.

## Conclusion

We have demonstrated that the (2*S*,3*R*)-*D-erythro* amino alcohol structures, commonly found in a wide range of sphingoid bases, can be synthesized in very good yields with high diastereoselectivity by an aldol condensation between the titanium enolate derived from an iminoglycinate that bears the (+)-(1*R*,2*R*,5*R*)-2-hydroxy-3-pinanone group as chiral auxiliary, and the appropriate aldehydes. This methodology has been shown to be practical, highly versatile and amenable to the synthesis of structurally more elaborate compounds related to sphingolipids.

## Experimental

### General methods

Optical rotations were measured with a Perkin-Elmer 241 polarimeter for samples in a 10 cm cell at  $22 \pm 2$  °C. Specific rotations  $[\alpha]_D$  are given in units of  $10^{-1}$  deg  $\text{cm}^2 \text{g}^{-1}$ . Analytical

TLC was performed on Silica Gel 60-F<sub>254</sub> (Merck, Darmstadt) with detection by quenching of fluorescence and/or by charring with 5% sulfuric acid in water. All commercial reagents were used as supplied.  $\text{Ti}(\text{OEt})_4$  was purchased from Aldrich, and contains  $\sim 15\%$   $\text{Ti}(\text{OPr-}i)_4$ .  $\text{ClTi}(\text{OEt})_3$  (containing  $\sim 10\%$   $\text{ClTi}(\text{OPr-}i)_3$ ) was prepared from  $\text{Ti}(\text{OEt})_4$  and  $\text{CH}_3\text{COCl}$  according to a known procedure.<sup>11</sup> Column chromatography was performed on Silica Gel 60 (Silicycle, Ontario).  $^1\text{H}$  NMR spectra were recorded at 300, 500, or 600 MHz. First order proton chemical shifts  $\delta_{\text{H}}$  are referenced to either residual  $\text{CHCl}_3$  ( $\delta_{\text{H}}$  7.24 ppm,  $\text{CDCl}_3$ ),  $\text{CDHCl}_2$  ( $\delta_{\text{H}}$  5.30 ppm,  $\text{CD}_2\text{Cl}_2$ ) or residual  $\text{CD}_2\text{HOD}$  ( $\delta_{\text{H}}$  3.30 ppm,  $\text{CD}_3\text{OD}$ ), or internal acetone ( $\delta_{\text{H}}$  2.225 ppm,  $\text{D}_2\text{O}$ ).  $^{13}\text{C}$  NMR spectra are reported to the second decimal; although it is expected that the reproducibility of chemical shifts will only be accurate to one tenth of a ppm, the reported data often include resonances separated by less than 0.1 ppm. Organic solutions were dried with anhydrous  $\text{Na}_2\text{SO}_4$  prior to concentration under vacuum at  $<40$  °C (bath). Microanalyses and electrospray mass spectra were performed by the analytical services of this department.

### General procedure A: aldol condensation

To a solution of iminoglycinate **5** (6.0 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (4 mL) was added a solution of  $\text{ClTi}(\text{OEt})_3$  (15.0 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (8 mL) at 0 °C under argon; followed by the addition of  $\text{Et}_3\text{N}$  (3.5 mL), a solution of the aldehyde (6.6 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (10 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 5–6 h, and quenched by addition of brine (30 mL). The mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (20 mL) and the organic phase was separated; the aqueous phase was extracted with more  $\text{CH}_2\text{Cl}_2$  ( $2 \times 50$  mL), and organic layers were combined, dried and concentrated. Chromatography on silica gel (pretreated with 15%  $\text{Et}_3\text{N}$  in eluent) afforded the desired compounds.

For the condensation with acrolein, we also employed  $\text{ClTi}(\text{OPr-}i)_3$  as reagent in a similar fashion (not shown in the experimental section). Ethyl and isopropyl esters were obtained as a 1:1 mixture of single diastereoisomers in 70% yield.

### General procedure B: acid hydrolysis of imines

The imines (4.6 mmol) were dissolved in a mixture of 1.0 N HCl (32 mL) and THF (8 mL) and the mixture was stirred for 3 days at room temperature. The mixture was extracted with  $\text{Et}_2\text{O}$  ( $2 \times 20$  mL), and the organic phase containing mainly the auxiliary was evaporated. The aqueous phase was neutralized to pH 8 with a solution of sat.  $\text{NaHCO}_3$ , and extracted with  $\text{CH}_2\text{Cl}_2$  until no more desired compounds could be detected by TLC. The combined extracts were dried and concentrated. Column chromatography on silica gel gave the desired amino esters.

### General procedure C: reduction of the amino esters

**Reduction with  $\text{LiAlH}_4$ .** To a solution of amino ester (1.5 mmol) in anhydrous THF (35 mL) at 0 °C, was added  $\text{LiAlH}_4$  (15 mmol) in small portions under argon; the mixture was heated at reflux for 3 days. The reaction was cooled and the mixture was filtered through a thin pad of silica gel using  $\text{CH}_2\text{Cl}_2$ – $\text{MeOH}$ – $\text{NH}_4\text{OH}$  (100:15:2) as eluent. After concentration, the residue was purified by column chromatography to provide the desired sphingoids.



**Reduction with LiBH<sub>4</sub>.** To a solution of amino ester (2.5 mmol) in methanol (15 mL) was added dropwise a solution of 2 M LiBH<sub>4</sub> in THF (7.5 mL, 15 mmol) at room temperature. The reaction was continued for 3 days and concentrated. The residue was loaded onto a thin pad of silica gel and eluted with CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH (100:15:2) to afford the crude product. After concentration, the residue was purified by column chromatography to give the desired sphingoids.

#### General procedure D: oxidation with Dess–Martin periodinane (DMP)

To a suspension of DMP (8.0 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (45 mL), was added pyridine (1.5 mL); the resulting slurry was stirred until all the reagents dissolved. A solution of alcohol (7.9 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise and the reaction was continued at room temperature for 5 h. A solution of sat. brine (20 mL) and sat. Na<sub>2</sub>SO<sub>3</sub> (20 mL) was added and the organic phase was separated; the aqueous phase was extracted with more CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL), and the organic extracts were combined, washed with water (1 × 100 mL) and brine (1 × 40 mL), dried and evaporated. The desired aldehydes were obtained after column chromatography.

**Ethyl {1*R*-[1*α*,2*β*,3(2*R*,3*R*),5*α*]}-3-hydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1]hept-3-ylidene)amino]-4-pentenoate (7).** This compound was prepared according to the general procedure A using ClTi(OEt)<sub>3</sub> as reagent. Compound 7 was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 4:1) and was found to contain ~10% isopropyl ester. Yield: 72%. *R*<sub>f</sub>: 0.43 (hexane–EtOAc 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): δ<sub>H</sub> 5.88 (ddd, 1H, *J* = 17.0, 10.5, 6.2 Hz), 5.38 (ddd, 1H, *J* = 17.0, 1.5, 1.5 Hz), 5.22 (ddd, 1H, *J* = 10.6, 1.5, 1.5 Hz), 4.62 (dd, 1H, *J* = 6.3, 6.3 Hz), 4.15–4.25 (m, 3H), 3.22 (broad s, 1H), 2.56 (dd, 1H, *J* = 18.0, 3.0 Hz), 2.53 (ddd, 1H, *J* = 18.0, 2.6, 2.6 Hz), 2.47 (broad s, 1H), 2.34 (ddd, 1H, *J* = 10.7, 6, 6, 2.3 Hz), 2.08 (dd, 1H, *J* = 5.9, 5.9 Hz), 2.03 (ddd, 1H, *J* = 6.0, 6.0, 3.0 Hz), 1.54 (d, 1H, *J* = 10.7 Hz), 1.50 (s, 3H), 1.33 (s, 3H), 1.24 (t, 3H, *J* = 7.1 Hz), 0.87 (s, 3H); for the isopropyl ester, all signals overlap with the ethyl ester except the signal at 5.05 (sept, 1H, *J* = 6.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz): δ<sub>C</sub> 180.66, 169.94, 136.50, 116.99, 76.71, 73.77, 67.00, 61.14, 50.22, 38.60, 38.39, 34.15, 28.18, 27.95, 27.26, 22.74, 14.13. HRMS *m/z* calc'd for C<sub>17</sub>H<sub>28</sub>NO<sub>4</sub> (M + H<sup>+</sup>): 310.2018; found 310.2018.

**Ethyl (2*R*,3*R*)-2-amino-3-hydroxy-4-pentenoate (8).** This compound was prepared according to the general procedure B. Compound 8 (containing trace amounts of isopropyl ester) was obtained by chromatography on silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH–NH<sub>4</sub>OH 100:2.5:1). Yield: 82%. *R*<sub>f</sub>: 0.27 (CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH 100:5:1). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz): δ<sub>H</sub> 5.73 (ddd, 1H, *J* = 16.7, 10.5, 6.5 Hz), 5.33 (ddd, 1H, *J* = 17.0, 1.6, 1.6 Hz), 5.21 (ddd, 1H, *J* = 10.5, 1.5, 1.5 Hz), 4.39 (dddd, 1H, *J* = 5.2, 5.2, 1.4, 1.4 Hz), 4.19 (dq, 1H, *J* = 10.8, 7.2 Hz), 4.16 (dq, 1H, *J* = 10.8, 7.2 Hz), 3.61 (d, 1H, *J* = 5.0 Hz), 1.26 (t, 3H, *J* = 7.0 Hz); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): δ<sub>C</sub> 173.16, 135.57, 117.33, 72.63, 61.18, 58.45, 14.178. HRMS *m/z* calc'd for C<sub>7</sub>H<sub>14</sub>NO<sub>3</sub> (M + H<sup>+</sup>): 160.0974; found 160.0974. Anal. calc'd for C<sub>7</sub>H<sub>13</sub>NO<sub>3</sub>: C, 52.82; H, 8.23; N, 8.80; found: C, 52.92; H, 8.36; N, 8.31%.

**(2*S*,3*R*)-2-Aminopent-4-ene-1,3-diol (1).** This compound was prepared according to the general procedure C using LiBH<sub>4</sub> as reducing reagent. Compound 1 was obtained as a single diastereoisomer by chromatography on silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH–NH<sub>4</sub>OH 100:10:1). Yield: 74%. [*a*<sub>D</sub><sup>25</sup>]: +18.5° (*c* 0.75, MeOH). *R*<sub>f</sub>: 0.27 (CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH 100:20:1). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz): δ<sub>H</sub> 5.90 (ddd, 1H, *J* = 17.0, 10.5, 6.5 Hz), 5.30 (ddd, 1H, *J* = 17.0, 1.6, 1.6 Hz), 5.21 (ddd, 1H, *J* = 10.5, 1.6, 1.6 Hz), 4.03 (dddd, 1H, *J* = 6.2, 6.1, 1.3, 1.3 Hz), 3.60 (dd, 1H, *J* = 10.9, 4.5 Hz), 3.50 (dd, 1H, *J* = 10.9, 6.9 Hz), 2.77 (ddd, 1H, *J* = 6.8, 6.4, 4.5 Hz); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): δ<sub>C</sub> 139.34, 117.08, 75.33, 64.24, 57.80. HRMS *m/z* calc'd for C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>Na (M + Na<sup>+</sup>): 140.0682; found 140.0680. Anal. calc'd for C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>: C, 51.26; H, 9.46; N, 11.96; found: C, 51.28; H, 9.57; N, 11.36%.

**Ethyl {1*R*-[1*α*,2*β*,3(2*R*,3*R*),5*α*]}-3-hydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1]hept-3-ylidene)amino]hexadecanoate (10a).** This compound was prepared according to the general procedure A using ClTi(OEt)<sub>3</sub> as reagent. Compound 10a (containing trace amounts of isopropyl ester) was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 6:1). Yield: 87%. *R*<sub>f</sub>: 0.29 (hexane–EtOAc 4:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): δ<sub>H</sub> 4.19 (dq, 2H, *J* = 7.2, 2.8 Hz), 4.11 (d, 1H, *J* = 6.3 Hz), 4.07 (m, 1H), 3.01 (br s, 1H), 2.58 (dd, 1H, *J* = 18.0, 3.0 Hz), 2.53 (ddd, 1H, *J* = 18.0, 2.5, 2.5 Hz), 2.35 (dddd, 1H, *J* = 10.7, 6.0, 6.0, 2.3 Hz), 2.09 (dd, 1H, *J* = 5.9, 5.8 Hz), 2.04 (ddd, 1H, *J* = 6.0, 5.9, 3.0 Hz), 1.55 (d, 1H, *J* = 10.7 Hz), 1.50 (s, 3H), 1.33 (s, 3H), 1.25 (t, 3H, *J* = 7.1 Hz), 1.25–1.50 (m, 24H), 0.88 (t, 3H, *J* = 7.0 Hz), 0.87 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ<sub>C</sub> 180.37, 170.59, 76.74, 72.62, 67.07, 61.12, 50.13, 38.64, 38.42, 34.10, 32.78, 31.92, 29.68–29.61 (7C), 29.34, 28.31, 28.03, 27.29, 25.52, 22.80, 22.68, 14.16, 14.10. HRMS *m/z* calc'd for C<sub>28</sub>H<sub>52</sub>NO<sub>4</sub> (M + H<sup>+</sup>): 466.3891; found 466.3893.

**Ethyl {1*R*-[1*α*,2*β*,3(2*R*,3*R*),5*α*]}-3-hydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1]hept-3-ylidene)amino]octadecanoate (10b).** This compound was prepared according to general procedure A using ClTi(OEt)<sub>3</sub> as reagent. Compound 10b (containing trace amounts of isopropyl ester) was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 6:1). Yield: 84%. *R*<sub>f</sub>: 0.34 (hexane–EtOAc 4:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): δ<sub>H</sub> 4.15 (dq, 2H, *J* = 7.2, 2.3 Hz), 4.09 (d, 1H, *J* = 6.0 Hz), 4.04 (m, 1H), 3.22 (br s, 1H), 2.53 (dd, 1H, *J* = 18.0, 2.5 Hz), 2.49 (ddd, 1H, *J* = 18.0, 2.5, 2.5 Hz), 2.32 (dddd, 1H, *J* = 10.8, 6.0, 5.9, 2.3 Hz), 2.06 (dd, 1H, *J* = 5.9, 5.9 Hz), 2.01 (ddd, 1H, *J* = 6.0, 5.9, 3.0 Hz), 1.52 (d, 1H, *J* = 10.7 Hz), 1.48 (s, 3H), 1.30 (s, 3H), 1.24 (t, 3H, *J* = 7.2 Hz), 1.25–1.50 (m, 28H), 0.85 (t, 3H, *J* = 6.8 Hz), 0.87 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ<sub>C</sub> 180.43, 170.54, 76.75, 72.65, 67.09, 61.10, 50.14, 38.64, 38.42, 34.06, 32.78, 31.92, 29.69–29.62 (9C), 29.35, 28.29, 28.02, 27.28, 25.55, 22.79, 22.68, 14.15, 14.10. HRMS *m/z* calc'd for C<sub>30</sub>H<sub>56</sub>NO<sub>4</sub> (M + H<sup>+</sup>): 494.4204; found 494.4202.

**Ethyl {1*R*-[1*α*,2*β*,3(2*R*,3*R*),5*α*]}-3-hydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1]hept-3-ylidene)amino]icosanoate (10c).** This compound was prepared according to the general procedure A using ClTi(OEt)<sub>3</sub> as reagent. Compound 10c (containing trace amounts of isopropyl ester) was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 6:1). Yield: 83%. *R*<sub>f</sub>: 0.34 (hexane–EtOAc 4:1). <sup>1</sup>H NMR

(CDCl<sub>3</sub>, 500 MHz):  $\delta_{\text{H}}$  4.17 (dq, 2H,  $J = 7.1, 2.0$  Hz), 4.10 (d, 1H,  $J = 6.1$  Hz), 4.07 (m, 1H), 3.20 (br s, 1H), 2.57 (dd, 1H,  $J = 18.0, 2.8$  Hz), 2.50 (ddd, 1H,  $J = 18.0, 2.5, 2.5$  Hz), 2.33 (dddd, 1H,  $J = 10.8, 6.0, 5.9, 2.3$  Hz), 2.06 (dd, 1H,  $J = 5.9, 5.9$  Hz), 2.02 (ddd, 1H,  $J = 5.9, 5.8, 2.8$  Hz), 1.52 (d, 1H,  $J = 10.9$  Hz), 1.50 (s, 3H), 1.31 (s, 3H), 1.22 (t, 3H,  $J = 7.2$  Hz), 1.25–1.50 (m, 32H), 0.88 (t, 3H,  $J = 7.0$  Hz), 0.87 (s, 3H);  $^{13}\text{C}$  NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta_{\text{C}}$  180.35, 170.55, 76.66, 72.61, 67.05, 61.08, 50.13, 42.90, 38.60, 38.40, 34.07, 32.76, 31.90, 29.33–29.67 (11C), 28.27, 28.03, 27.26, 25.52, 22.77, 22.65, 14.13, 14.08. HRMS  $m/z$  calc'd for C<sub>32</sub>H<sub>60</sub>NO<sub>4</sub> (M + H<sup>+</sup>): 522.4517; found 522.4519.

**Ethyl (2R,3R)-2-amino-3-hydroxyhexadecanoate (11a).** This compound was prepared according to the general procedure B. Compound 11a was obtained by chromatography on silica gel (eluent: Et<sub>2</sub>O–CH<sub>3</sub>OH 25:1). Yield: 80%.  $R_f$ : 0.31 (Et<sub>2</sub>O–MeOH 20:1).  $[\alpha]_{\text{D}}^{25}$ : –7.4 (c 0.50, MeOH).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  4.33 (dq, 1H,  $J = 10.8, 7.1$  Hz), 4.29 (dq, 1H,  $J = 10.8, 7.1$  Hz), 4.04 (d, 1H,  $J = 3.3$  Hz), 3.99 (ddd, 1H,  $J = 9.0, 3.7, 3.7$  Hz), 1.59 (m, 1H), 1.50 (m, 1H), 1.32 (t, 3H,  $J = 7.1$  Hz), 1.25–1.40 (m, 22H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{C}}$  168.34, 70.74, 63.54, 58.96, 33.63, 33.07, 30.85, 30.79, 30.77, 30.75, 30.68, 30.57, 30.46, 30.42, 26.91, 23.73, 14.44, 14.43. HRMS  $m/z$  calc'd for C<sub>18</sub>H<sub>38</sub>NO<sub>3</sub> (M + H<sup>+</sup>): 316.2846; found 316.2845. Anal. calc'd for C<sub>18</sub>H<sub>37</sub>NO<sub>3</sub>: C, 61.43; H, 10.88; N, 3.98; found: C, 61.47; H, 11.07; N, 3.73%.

**Ethyl (2R,3R)-2-amino-3-hydroxyoctadecanoate (11b).** This compound was prepared according to the general procedure B. Compound 11b was obtained by chromatography on silica gel (eluent: Et<sub>2</sub>O–CH<sub>3</sub>OH 25:1). Yield: 84%.  $R_f$ : 0.34 (Et<sub>2</sub>O–MeOH 20:1).  $[\alpha]_{\text{D}}^{25}$ : –9.6 (c 0.57, MeOH).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  4.32 (dq, 1H,  $J = 10.8, 7.2$  Hz), 4.28 (dq, 1H,  $J = 10.8, 7.2$  Hz), 4.04 (d, 2H,  $J = 3.3$  Hz), 3.99 (ddd, 1H,  $J = 8.7, 5.0, 3.3$  Hz), 1.59 (m, 1H), 1.50 (m, 1H), 1.32 (t, 3H,  $J = 7.2$  Hz), 1.25–1.40 (m, 26H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{C}}$  168.32, 70.73, 63.54, 58.95, 33.64, 33.07, 30.79–30.43 (10C), 26.92, 23.72, 14.45 (2C). HRMS  $m/z$  calc'd for C<sub>20</sub>H<sub>40</sub>NO<sub>3</sub>: 344.3159 (M + H<sup>+</sup>); found 344.3159. Anal. calc'd for C<sub>20</sub>H<sub>41</sub>NO<sub>3</sub>: C, 63.21; H, 11.14; N, 3.69; found: C, 63.31; H, 11.25; N, 3.48%.

**Ethyl (2R,3R)-2-amino-3-hydroxyicosanoate (11c).** This compound was prepared according to the general procedure B. Compound 11c was obtained by chromatography on silica gel (eluent: Et<sub>2</sub>O–CH<sub>3</sub>OH 25:1). Yield: 85%.  $R_f$ : 0.35 (Et<sub>2</sub>O–MeOH 20:1).  $[\alpha]_{\text{D}}^{25}$ : –6.8 (c 0.6, MeOH).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  4.27 (dq, 1H,  $J = 10.8, 7.2$  Hz), 4.23 (dq, 1H,  $J = 10.8, 7.2$  Hz), 3.87 (ddd, 1H,  $J = 9.0, 8.9, 3.8$  Hz), 3.76 (d, 1H,  $J = 3.8$  Hz), 1.52–1.60 (m, 2H), 1.30 (t, 3H,  $J = 7.2$  Hz), 1.25–1.40 (m, 30H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{C}}$  174.37, 74.37, 61.98, 60.37, 33.81, 33.07, 30.90–30.47 (12C), 27.02, 23.74, 14.56, 14.44. HRMS  $m/z$  calc'd for C<sub>22</sub>H<sub>46</sub>NO<sub>3</sub> (M + H<sup>+</sup>): 372.3472; found 372.3471. Anal. calc'd for C<sub>22</sub>H<sub>45</sub>NO<sub>3</sub>: C, 64.75; H, 11.36; N, 3.43; found: C, 64.78; H, 11.43; N, 3.27%.

**(2S,3R)-2-Aminohexadecane-1,3-diol (2a).** This compound was prepared according to the general procedure C using LiAlH<sub>4</sub> as reducing reagent. Compound 2a was obtained by chromatography on silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH–NH<sub>4</sub>OH 100:10:1). Yield: 85%.  $[\alpha]_{\text{D}}^{25}$ : +8.7 (c 1.0, MeOH).  $R_f$ : 0.21 (CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH 100:10:2).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  3.72 (dd,

1H,  $J = 10.9, 4.2$  Hz), 3.50 (ddd, 1H,  $J = 8.0, 5.5, 3.0$  Hz), 3.46 (dd, 1H,  $J = 10.9, 7.6$  Hz), 2.71 (ddd, 1H,  $J = 7.6, 5.4, 4.2$  Hz), 1.52 (m, 2H), 1.25–1.45 (m, 22H), 0.9 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{C}}$  74.03, 64.30, 58.15, 34.40, 33.07, 30.82–30.75 (8C), 27.03, 23.73, 14.42. HRMS  $m/z$  calc'd for C<sub>16</sub>H<sub>36</sub>NO<sub>2</sub> (M + H<sup>+</sup>): 274.2741; found 274.2743. Anal. calc'd for C<sub>16</sub>H<sub>35</sub>NO<sub>2</sub>: C, 70.28; H, 12.90; N, 5.12; found: C, 69.65; H, 12.91; N, 5.04%.

**(2S,3R)-2-Aminooctadecane-1,3-diol (2b).** This compound was prepared according to the general procedure C using LiAlH<sub>4</sub> as reducing reagent. Compound 2b was obtained by chromatography on silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH–NH<sub>4</sub>OH 100:10:1). Yield: 78%.  $[\alpha]_{\text{D}}^{25}$ : +8.1 (c 1.0, MeOH). lit.<sup>21</sup>  $[\alpha]_{\text{D}}^{25}$ : +1.83 (c 1.0, pyridine), lit.<sup>24e</sup>  $[\alpha]_{\text{D}}^{25}$ : +5.7 (c 2.74, CHCl<sub>3</sub>–MeOH 4:1).  $R_f$ : 0.41 (CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH 100:20:2).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  3.72 (dd, 1H,  $J = 10.9, 4.2$  Hz), 3.49 (ddd, 1H,  $J = 8.0, 5.5, 3.0$  Hz), 3.46 (dd, 1H,  $J = 10.9, 7.6$  Hz), 2.70 (ddd, 1H,  $J = 7.6, 5.4, 4.2$  Hz), 1.52 (m, 2H), 1.25–1.45 (m, 26H), 0.9 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{H}}$  74.07, 64.37, 58.15, 34.41, 33.07, 30.08–30.75 (10C), 27.04, 23.73, 14.43. HRMS  $m/z$  calc'd for C<sub>18</sub>H<sub>40</sub>NO<sub>2</sub> (M + H<sup>+</sup>): 302.3054; found 302.3055. Anal. calc'd for C<sub>18</sub>H<sub>39</sub>NO<sub>2</sub>: C, 71.70; H, 13.04; N, 4.65; found: C, 71.46; H, 12.95; N, 4.58%.

**(2S,3R)-2-Aminoicosane-1,3-diol (2c).** This compound was prepared according to the general procedure C using LiAlH<sub>4</sub> as reducing reagent. Compound 2c was obtained by chromatography on silica gel (eluent: CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH–NH<sub>4</sub>OH 100:10:1). Yield: 81%.  $[\alpha]_{\text{D}}^{25}$ : +6.5 (c 0.9, CHCl<sub>3</sub>–MeOH 4:1).  $R_f$ : 0.19 (CH<sub>2</sub>Cl<sub>2</sub>–MeOH–NH<sub>4</sub>OH 100:10:2).  $^1\text{H}$  NMR (CD<sub>3</sub>OD, 600 MHz):  $\delta_{\text{H}}$  3.72 (dd, 1H,  $J = 10.9, 4.2$  Hz), 3.49 (ddd, 1H,  $J = 8.0, 5.5, 3.0$  Hz), 3.46 (dd, 1H,  $J = 10.9, 7.6$  Hz), 2.70 (ddd, 1H,  $J = 7.5, 5.4, 4.2$  Hz), 1.53 (m, 2H), 1.25–1.44 (m, 30H), 0.9 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD, 125 MHz):  $\delta_{\text{H}}$  74.11, 64.37, 58.15, 34.41, 33.07, 30.78–30.50 (12C), 27.039, 23.74, 14.43. HRMS  $m/z$  calc'd for C<sub>20</sub>H<sub>44</sub>NO<sub>2</sub> (M + H<sup>+</sup>): 330.3366; found 330.3363. Anal. calc'd for C<sub>20</sub>H<sub>43</sub>NO<sub>2</sub>: C, 72.89; H, 13.15; N, 4.25; found: C, 72.56; H, 13.04; N, 4.16%.

**(2R)-2-Methoxymethoxyhexadecanal (14).** This compound was prepared according to the general procedure D. Compound 14 was obtained by chromatography on silica gel (eluent: hexane–EtOAc 20:1). Yield: 90%.  $[\alpha]_{\text{D}}^{25}$ : +24.7 (c 1.0, CHCl<sub>3</sub>).  $R_f$ : 0.51 (hexane–EtOAc 6:1).  $^1\text{H}$  NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz):  $\delta_{\text{H}}$  9.58 (d, 1H,  $J = 2.0$  Hz), 4.70 (d, 1H,  $J = 7.0$  Hz), 4.68 (d, 1H,  $J = 7.0$  Hz), 3.85 (ddd, 1H,  $J = 6.6, 5.6, 2.0$  Hz), 3.39 (s, 3H), 1.64 (m, 2H), 1.41 (m, 2H), 1.20–1.35 (m, 22H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>2</sub>Cl<sub>2</sub>, 125 MHz):  $\delta_{\text{C}}$  203.28, 97.15, 82.86, 56.12, 32.32, 30.37, 30.08–29.75 (9C), 25.21, 23.08, 14.26. HRMS  $m/z$  calc'd for C<sub>18</sub>H<sub>36</sub>O<sub>3</sub>Na (M + Na<sup>+</sup>): 323.2562; found: 323.2564. Anal. calc'd for C<sub>18</sub>H<sub>36</sub>O<sub>3</sub>: C, 71.95; H, 12.08; found: C, 71.83; H, 12.19%.

**(2S)-2-Methoxymethoxyhexadecanal (15).** This compound was prepared according to the general procedure D. Compound 15 was obtained by chromatography on silica gel (eluent: hexane–EtOAc 20:1). Yield: 94%.  $[\alpha]_{\text{D}}^{25}$ : –24.3 (c 0.9, CHCl<sub>3</sub>).  $R_f$ : 0.50 (hexane–EtOAc 6:1).  $^1\text{H}$  NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz):  $\delta_{\text{H}}$  9.58 (d, 1H,  $J = 2.0$  Hz), 4.70 (d, 1H,  $J = 7.0$  Hz), 4.68 (d, 1H,  $J = 7.0$  Hz), 3.86 (ddd, 1H,  $J = 7.6, 5.6, 2.2$  Hz), 3.39 (s, 3H), 1.62–1.68 (m, 2H), 1.40 (m, 2H), 1.25–1.35 (m, 22H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (CD<sub>2</sub>Cl<sub>2</sub>, 125 MHz):  $\delta_{\text{C}}$  203.28, 97.15, 82.84, 56.12, 32.32,

30.37, 30.08–29.75 (9C), 25.21, 23.08, 14.26. HRMS  $m/z$  calc'd for  $C_{18}H_{36}O_3Na$  ( $M + Na^+$ ): 323.2562; found: 323.2561. Anal. calc'd for  $C_{18}H_{36}O_3$ : C, 71.95; H, 12.08; found: C, 71.62; H, 12.14%.

**Ethyl {1*R*-[1 $\alpha$ ,2 $\beta$ ,3(2*R*,3*R*,4*R*),5 $\alpha$ ]-3,4-dihydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1] hept-3-ylidene)amino]octadecanoate (16).** This compound was prepared according to the general procedure A using  $ClTi(OEt)_3$  as reagent. Compound 16 (containing trace amounts of isopropyl ester) was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 6:1). Yield: 91%.  $R_f$ : 0.31 (hexane–EtOAc 3:1).  $^1H$  NMR ( $CDCl_3$ , 600 MHz):  $\delta_H$  4.78 (d, 1H,  $J = 6.7$  Hz), 4.58 (d, 1H,  $J = 6.8$  Hz), 4.24–4.30 (m, 2H), 4.17 (dt, 2H,  $J = 7.1, 0.9$  Hz), 3.67 (dt, 1H,  $J = 8.5, 3.2$  Hz), 3.41 (s, 3H), 3.23 (br s, 1H), 2.58 (broad s, 2H), 2.32 (ddd, 1H,  $J = 10.7, 6.0, 5.8$  Hz), 2.06 (dd, 1H,  $J = 6.0, 5.9$  Hz), 2.02 (ddd, 1H,  $J = 6.0, 5.9, 3.0$  Hz), 1.58–1.70 (m, 2H), 1.52 (d, 1H,  $J = 10.7$  Hz), 1.47 (s, 3H), 1.33 (s, 3H), 1.25 (t, 3H,  $J = 7$  Hz), 1.25–1.30 (m, 24H), 0.88 (t, 3H,  $J = 7.0$  Hz), 0.87 (s, 3H);  $^{13}C$  NMR ( $CDCl_3$ , 125 MHz):  $\delta_C$  180.27, 170.21, 96.45, 78.92, 76.71, 73.82, 64.63, 61.07, 55.81, 50.23, 38.64, 38.43, 34.13, 31.91, 30.23, 29.77–29.35 (7C), 28.26, 28.02, 27.27, 25.36, 22.78, 22.67, 14.16, 14.09. HRMS  $m/z$  calc'd for  $C_{32}H_{60}NO_6$  ( $M + H^+$ ): 554.4421; found 554.4423.

**Ethyl {1*R*-[1 $\alpha$ ,2 $\beta$ ,3(2*R*,3*R*,4*R*),5 $\alpha$ ]-3,4-dihydroxy-2-[(2-hydroxy-2,6,6-trimethylbicyclo[3,1,1] hept-3-ylidene)amino]octadecanoate (17).** This compound was prepared according to the general procedure A using  $ClTi(OEt)_3$  as reagent. Compound 17 (containing trace amounts of isopropyl ester) was obtained as a single diastereoisomer by chromatography on silica gel (eluent: hexane–EtOAc 6:1). Yield: 83%.  $R_f$ : 0.32 (hexane–EtOAc 3:1).  $^1H$  NMR ( $CDCl_3$ , 600 MHz):  $\delta_H$  4.66 (d, 1H,  $J = 6.4$  Hz), 4.63 (d, 1H,  $J = 6.4$  Hz), 4.31 (d, 1H,  $J = 8.2$  Hz), 4.20 (quint, 2H,  $J = 7.0$  Hz), 4.12 (quint, 1H,  $J = 7.1$  Hz), 3.57 (ddd, 1H,  $J = 8, 5.9, 2$  Hz), 3.37 (s, 3H), 3.01 (broad s, 1H), 2.66 (dd, 1H,  $J = 8.2, 2.8$  Hz), 2.58 (ddd, 1H,  $J = 8.1, 2.5, 2.5$  Hz), 2.34 (dddd, 1H,  $J = 10.7, 6.0, 5.8, 2.5$  Hz), 2.08 (dd, 1H,  $J = 5.9, 5.9$  Hz), 2.03 (ddd, 1H,  $J = 6.0, 5.9, 2.9$  Hz), 1.74 (m, 1H), 1.64 (m, 1H), 1.52 (d, 1H,  $J = 10.7$  Hz), 1.48 (s, 3H), 1.32 (s, 3H), 1.24 (t, 3H,  $J = 7.0$  Hz), 1.25–1.30 (m, 24H), 0.88 (t, 3H,  $J = 7.0$  Hz), 0.85 (s, 3H);  $^{13}C$  NMR ( $CDCl_3$ , 125 MHz):  $\delta_C$  180.48, 170.99, 96.55, 77.94, 76.67, 73.43, 64.98, 61.18, 60.37, 55.86, 50.21, 38.62, 38.42, 34.01, 31.91, 31.06, 29.78–29.35 (8C), 28.26, 27.97, 27.28, 25.58, 22.81, 22.68, 14.18, 14.10. HRMS  $m/z$  calc'd for  $C_{32}H_{59}NO_6Na$  ( $M + Na^+$ ): 576.4240; found 576.4239.

**(2*R*,3*R*,4*R*)-2-Amino-3-hydroxyoctadecane-1,4-lactone hydrochloride (20).** This compound was prepared according to the general procedure B. Compound 20 was obtained as a single diastereoisomer by chromatography on silica gel (eluent:  $CH_2Cl_2$ – $CH_3OH$ – $NH_4OH$  100:2.5:1). Yield: 79%.  $R_f$ : 0.27 ( $CH_2Cl_2$ – $MeOH$ – $NH_4OH$  100:5:2).  $^1H$  NMR ( $CD_3OD$ , 600 MHz):  $\delta_H$  4.47 (d, 1H,  $J = 6.2$  Hz), 4.45 (d, 1H,  $J = 7.4$  Hz), 4.36 (d, 1H,  $J = 5.3$  Hz), 1.8 (quint, 2H,  $J = 7.5$  Hz), 1.24–1.50 (m, 24H), 0.89 (t, 3H,  $J = 7.0$  Hz).  $^{13}C$  NMR ( $CD_3OD$ , 125 MHz):  $\delta_C$  172.67, 89.78, 70.54, 52.15, 33.07, 32.91, 30.78, 30.77, 30.75, 30.74, 30.67, 30.57, 30.26, 26.60, 23.74, 14.43. HRMS  $m/z$  calc'd for  $C_{18}H_{36}NO_3$  ( $M + H^+$ ): 314.2690; found 314.2691. Anal. calc'd for  $C_{18}H_{35}NO_3$ : C, 68.97; H, 11.25; N, 4.47; found: C, 68.69; H, 11.36; N, 4.43%.

**(2*R*,3*R*,4*S*)-2-Amino-3-hydroxyoctadecane-1,4-lactone hydrochloride (21).** This compound was prepared according to the general procedure B. Compound 21 was obtained as a single diastereoisomer by chromatography on silica gel (eluent:  $CH_2Cl_2$ – $CH_3OH$ – $NH_4OH$  100:2.5:1). Yield: 83%.  $R_f$ : 0.26 ( $CH_2Cl_2$ – $MeOH$ – $NH_4OH$  100:5:2).  $^1H$  NMR ( $CD_3OD$ , 600 MHz):  $\delta_H$  4.52 (ddd, 1H,  $J = 5.2, 2.6, 2.6$  Hz), 4.50 (dd, 1H,  $J = 5.2, 5.0$  Hz), 4.43 (d, 1H,  $J = 5.0$  Hz), 1.82 (m, 1H), 1.72 (m, 1H), 1.48 (m, 1H), 1.25–1.40 (m, 22H), 0.89 (t, 3H,  $J = 7.0$  Hz);  $^{13}C$  NMR ( $CD_3OD$ , 125 MHz):  $\delta_C$  172.91, 84.93, 69.52, 54.40, 33.07, 30.87, 30.84, 30.78, 30.76, 30.72, 30.66, 30.60, 30.57, 30.46, 29.32, 26.33, 23.73, 14.43. HRMS  $m/z$  calc'd for  $C_{18}H_{36}NO_3$  ( $M + H^+$ ): 314.2690; found 314.2694. Anal. calc'd for  $C_{18}H_{35}NO_3HCl$ : C, 61.78; H, 10.37; N, 4.00; found: C, 61.50; H, 10.66; N, 3.74%.

**(2*S*,3*R*,4*R*)-2-Aminooctadecane-1,3,4-triol (D-*ribo*-phytosphingosine) (3).** This compound was prepared according to the general procedure C using  $LiAlH_4$  as reducing reagent. Compound 3 was obtained by chromatography on silica gel (eluent:  $CH_2Cl_2$ – $CH_3OH$ – $NH_4OH$  100:10:1). Yield 82%.  $[a]_D^{25}$ : +7.6 (c 0.7, pyridine); lit.<sup>22i</sup>  $[a]_D^{24}$ : +8.7 (c 0.8, pyridine); lit.<sup>22j</sup>  $[a]_D^{23}$ : +8.5 (c 0.9, pyridine).  $R_f$ : 0.13 ( $CH_2Cl_2$ – $MeOH$ – $NH_4OH$  100:10:2).  $^1H$  NMR ( $CD_3OD$ , 500 MHz):  $\delta_H$  3.75 (dd, 1H,  $J = 10.9, 4.2$  Hz), 3.56 (dd, 1H,  $J = 10.9, 6.6$  Hz), 3.51 (ddd, 1H,  $J = 8.3, 8.0, 3.0$  Hz), 3.33 (dd, 1H,  $J = 7.8, 5.6$  Hz), 2.94 (ddd, 1H,  $J = 6.4, 5.7, 4.2$  Hz), 1.73 (m, 1H), 1.55 (m, 1H), 1.25–1.40 (m, 24H), 0.9 (t, 3H,  $J = 7.0$  Hz);  $^{13}C$  NMR ( $CD_3OD$ , 125 MHz):  $\delta_C$  76.51, 74.51, 64.21, 55.70, 34.78, 33.08, 30.95–30.48 (9C), 26.61, 23.74, 14.44. HRMS  $m/z$  calc'd for  $C_{18}H_{40}NO_3$  ( $M + H^+$ ) 318.3002; found 318.3001. Anal. calc'd for  $C_{18}H_{39}NO_3$ : C, 68.09; H, 12.38; N, 4.41; found: C, 67.45; H, 12.53; N, 4.29%.

**(2*S*,3*R*,4*S*)-2-Aminooctadecane-1,3,4-triol (L-*lyxo*-phytosphingosine) (4).** This compound was prepared according to the general procedure C using  $LiAlH_4$  as reducing reagent. Compound 4 was obtained by chromatography on silica gel (eluent:  $CH_2Cl_2$ – $CH_3OH$ – $NH_4OH$  100:10:1). Yield: 80%.  $[a]_D^{25}$ : –10.0 (c 1.0, pyridine); lit.<sup>24e</sup>  $[a]_D^{25}$ : –7.4 (c 0.9, pyridine); lit.<sup>22j</sup>  $[a]_D^{23}$ : –6.2 (c 1.0, pyridine).  $R_f$ : 0.14 ( $CH_2Cl_2$ – $MeOH$ – $NH_4OH$  100:10:2).  $^1H$  NMR ( $CD_3OD$ , 600 MHz):  $\delta_H$  3.76 (dd, 1H,  $J = 10.9, 4.2$  Hz), 3.67 (ddd, 1H,  $J = 7.7, 4.8, 2.7$  Hz), 3.52 (dd, 1H,  $J = 10.9, 7.0$  Hz), 3.32 (dd, 1H,  $J = 7.0, 2.7$  Hz), 2.93 (ddd, 1H,  $J = 7.0, 7.0, 4.3$  Hz), 1.45–1.59 (m, 2H), 1.25–1.40 (m, 24H), 0.9 (t, 3H,  $J = 7.0$  Hz);  $^{13}C$  NMR ( $CD_3OD$ , 125 MHz):  $\delta_C$  75.31, 72.34, 64.71, 55.65, 34.64, 33.07, 30.86–30.46 (9C), 27.05, 23.73, 14.42. HRMS  $m/z$  calc'd for  $C_{18}H_{40}NO_3$  ( $M + H^+$ ): 318.3002; found 318.3002. Anal. calc'd for  $C_{18}H_{39}NO_3$ : C, 68.09; H, 12.38; N, 4.41; found: C, 67.70; H, 12.57; N, 4.33%.

## References

- (a) I. Pascher, *Biochim. Biophys. Acta*, 1976, **455**, 433–451; (b) J. C. M. Holthuis, T. Pomorski, R. J. Riggers, H. Sprong and G. van Meer, *Physiol. Rev.*, 2001, **81**, 1689–1723.
- I. Olsen and E. Jantzen, *Anaerobe*, 2001, 103–112.
- For a review, see: V. Daniel, D. V. Lynch and T. M. Dunn, *New Phytol.*, 2004, **161**, 677–702.
- T. F. Molinski, *Curr. Med. Chem.*, 2004, **3**, 197–220.
- (a) A. H. Merrill and C. C. Sweeley, in *Biochemistry of Lipids, Lipoproteins and Membranes*, ed. D. E. Vance and J. Vance, Elsevier, Amsterdam, 1996, vol. 31, pp. 309–339; (b) Y. A. Hannum, *Sphingolipid-Mediated Signal Transduction*, R. G. Landes Company,



- Austin, 1997; (c) S. A. Porcelli and R. L. Modlin, *Annu. Rev. Immunol.*, 1999, **17**, 297–329; (d) K. C. Nicolaou, J. Li and G. Zenke, *Helv. Chim. Acta*, 2000, **83**, 1977–2006; (e) V. Costantino, E. Fattorusso, A. Mangoni, M. Di Rosa and A. Ianaro, *J. Am. Chem. Soc.*, 1997, **119**, 12465–12470.
- 6 C. Rodriguez-Lafrasse, R. Rousson, S. Valla, P. Antignac, P. Louisot and M. T. Vanvier, *Biochem. J.*, 1997, **325**, 787–791.
- 7 A. Shamshiev, A. Donda, T. I. Prigozy, L. Mori, V. Chigorno, C. A. Benedict, L. Kappos, S. Sonnino, M. Kronenberg and G. De Libero, *Immunity*, 2000, **13**, 255–264.
- 8 (a) R. C. Dickson, E. E. Nagiec, M. Skrzypek, P. Tillman, G. B. Wells and R. L. Lester, *J. Biol. Chem.*, 1997, **272**, 30196–30200; (b) R. Schreiner, *Bioessays*, 1999, **21**, 1004–1010.
- 9 (a) T. Kawano, J. Cui, Y. Koezuka, Y. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki and M. Taniguchi, *Science*, 1997, **278**, 1626–1629; (b) E. Kobayashi, K. Motoki, Y. Yamaguchi, T. Uchida, H. Fukushima and Y. Koezuka, *Bioorg. Med. Chem.*, 1996, **4**, 615–619; (c) E. Kobayashi, K. Motoki, T. Uchida, H. Fukushima and Y. Koezuka, *Oncol. Res.*, 1995, **7**, 529–534; (d) M. Morita, K. Motoki, K. Akimoto, T. Natori, T. Sakai, E. Sawa, K. Yamaji, Y. Koezuka, E. Kobayashi and H. Fukushima, *J. Med. Chem.*, 1995, **38**, 2176–2187.
- 10 For reviews, see: (a) P. M. Koskinen and A. M. P. Koskinen, *Synthesis*, 1998, 1075–1091; (b) C. Curfman and D. Liotta, *Methods Enzymol.*, 1999, **311**, 391–457.
- 11 A. Solladié-Cavallo and J. L. Koessler, *J. Org. Chem.*, 1994, **59**, 3240–3242.
- 12 S. Li, J. Pang, W. K. Wilson and G. J. Schroeffer, Jr., *J. Labelled Compd. Radiopharm.*, 1999, **42**, 815–826.
- 13 T. Shioiri and N. Irako, *Tetrahedron*, 2000, **56**, 9129–9142.
- 14 Y. Vo-Hoang, L. Micouin, C. Ronet, G. Gachelin and M. Bonin, *ChemBioChem*, 2003, **4**, 27–33.
- 15 For examples of truncated sphingosine syntheses, see: (a) D. R. Bundle, C.-C. Ling and P. Zhang, *US Patent* WO 03/101937; *Chem. Abs.*, 2003, 140, 16928; (b) A. N. Rai and A. Basu, *Org. Lett.*, 2004, **6**, 2861–2863; (c) S. Torssell and P. Somfai, *Org. Biomol. Chem.*, 2004, **2**, 1643–1646. For examples of diastereoisomer syntheses of truncated sphingosine, see: (d) X. Zhang, W. Ni and W. A. van der Donk, *J. Org. Chem.*, 2005, **70**, 6685–6692; (e) H. Razavi and R. Polt, *Tetrahedron Lett.*, 1998, **39**, 3371–3374.
- 16 (a) J. R. Rich and D. R. Bundle, *Org. Lett.*, 2004, **6**, 897; (b) S. Jacques, J. R. Rich, C.-C. Ling and D. R. Bundle, *Org. Biomol. Chem.*, 2006, **4**, 142–154; (c) D. R. Bundle, J. R. Rich, S. Jacques, H. N. Yu, M. Nitz and C.-C. Ling, *Angew. Chem., Int. Ed.*, 2005, **44**, 7725–7729; (d) J. R. Rich and D. R. Bundle, *Chem.-Eur. J.*, 2006, **12**, 845–858.
- 17 C.-C. Ling and D. R. Bundle, unpublished work.
- 18 T. Oguri, N. Kaway and S. Yamada, *Chem. Pharm. Bull.*, 1978, **26**, 803.
- 19 (a) S. Kodato, M. Nakagawa and T. Hino, *Tetrahedron*, 1989, **45**, 7263–7280; (b) G. N. Nicholas and T. F. Molinski, *J. Am. Chem. Soc.*, 2000, **122**, 4011–4019.
- 20 (a) R. Wild and R. R. Schmidt, *Liebigs Ann.*, 1995, 755–764; (b) E. J. Reist and P. H. Christie, *J. Org. Chem.*, 1970, **35**, 3521–3524.
- 21 R. C. So, R. Ndonye, D. P. Izmirian, S. K. Richardson, R. L. Guerrero and A. R. Howell, *J. Org. Chem.*, 2004, **69**, 3233–3235, and references therein.
- 22 (a) O. Plettenburg, V. Bodmer-Narkevitch and C.-H. Wong, *J. Org. Chem.*, 2002, **67**, 4559–4564; (b) S.-Y. Luo, S. R. Thopate, C.-Y. Hsu and S.-C. Hung, *Tetrahedron Lett.*, 2002, **43**, 4889–4892; (c) S. Figueroa-Pérez and R. R. Schmidt, *Carbohydr. Res.*, 2000, **328**, 95–102; (d) A. Graziani, P. Passacantelli, G. Piancatelli and S. Tani, *Tetrahedron: Asymmetry*, 2000, **11**, 3921–3937; (e) T. Murakami and K. Taguchi, *Tetrahedron*, 1999, **55**, 989–1004; (f) Y.-L. Li, X.-H. Mao and Y.-L. Wu, *J. Chem. Soc., Perkin Trans. 1*, 1995, 1559–1563; (g) K. Matsumoto, T. Ebata and H. Matsushita, *Carbohydr. Res.*, 1995, **279**, 93–106; (h) R. Wild and R. R. Schmidt, *Tetrahedron: Asymmetry*, 1994, **5**, 2195–2208; (i) T. Murakami, H. Minamikawa and M. Hato, *Tetrahedron Lett.*, 1994, **35**, 745–748; (j) R. R. Schmidt and T. Maier, *Carbohydr. Res.*, 1988, **174**, 169–180.
- 23 (a) A. J. Ndakala, M. Hashemzadeh, R. C. So and A. R. Howell, *Org. Lett.*, 2002, **4**, 1719–1722; (b) H. Azuma, S. Tamagaki and K. Ogino, *J. Org. Chem.*, 2000, **65**, 3538–3541; (c) H. Takikawa, S.-E. Muto and K. Mori, *Tetrahedron*, 1998, **54**, 3141–3150; (d) R. Imashiro, O. Sakurai, T. Yamashita and H. Horikawa, *Tetrahedron*, 1998, **54**, 10657–10670; (e) M. Shimizu, I. Wakioka and T. Fujisawa, *Tetrahedron Lett.*, 1997, **38**, 6027–6030; (f) H. Yoda, T. Oguchi and K. Takabe, *Tetrahedron: Asymmetry*, 1996, **7**, 2113–2116; (g) A. Dondoni, G. Fantin, M. Fogagnolo and P. Pedrini, *J. Org. Chem.*, 1990, **55**, 1439–1446; (h) S. Sugiyama, M. Honda and T. Komori, *Liebigs Ann. Chem.*, 1990, 1069–1078.
- 24 (a) T. Ayad, Y. Génisson, A. Verdu, M. Baltas and L. Gorrichon, *Tetrahedron Lett.*, 2003, **44**, 579–582; (b) H.-K. Lee, E.-K. Kim and C.-S. Pak, *Tetrahedron Lett.*, 2002, **43**, 9641–9644; (c) T. Nakamura and M. Shiozaki, *Tetrahedron*, 2001, **57**, 9087–9092; (d) C. Martin, W. Prünck, M. Bortoloussi and R. Bloch, *Tetrahedron: Asymmetry*, 2000, **11**, 1585–1592; (e) L. He, H.-S. Byun and R. Bittman, *J. Org. Chem.*, 2000, **65**, 7618–7626; (f) R. A. Fernandes and P. Kumar, *Tetrahedron Lett.*, 2000, **41**, 10309–10312; (g) O. Shiota, K. Nakanishi and N. Berova, *Tetrahedron*, 1999, **55**, 13643–13658; (h) T. Nakamura and M. Shiozaki, *Tetrahedron Lett.*, 1999, **40**, 9063–9064; (i) S. Li, J. Pang, W. K. Wilson and G. J. Schroeffer, Jr., *Tetrahedron: Asymmetry*, 1999, **10**, 1697–1707; (j) A. G. H. Wee and F. Tang, *Tetrahedron Lett.*, 1996, **37**, 6677–6680; (k) G.-Q. Lin and Z.-C. Shi, *Tetrahedron*, 1996, **52**, 2187–2192; (l) S. Kobayashi, T. Hayashi and T. Kawasaki, *Tetrahedron Lett.*, 1994, **35**, 9573–9576.
- 25 D. B. Dess and J. C. Martin, *J. Org. Chem.*, 1983, **48**, 4155–4156.
- 26 K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K.-S. Jeong, H.-L. Kwong, K. Morikawa, Z.-M. Wang, D. Xu and X.-L. Zhang, *J. Org. Chem.*, 1992, **57**, 2768–2771.